Rebuzzi, Sara Elena
Signori, Alessio
Banna, Giuseppe Luigi
Gandini, Annalice
Fornarini, Giuseppe https://orcid.org/0000-0003-4754-6572
Damassi, Alessandra
Maruzzo, Marco
De Giorgi, Ugo
Basso, Umberto
Chiellino, Silvia
Galli, Luca
Zucali, Paolo Andrea
Fantinel, Emanuela
Naglieri, Emanuele
Procopio, Giuseppe
Milella, Michele
Boccardo, Francesco
Fratino, Lucia
Pipitone, Stefania
Ricotta, Riccardo
Panni, Stefano
Mollica, Veronica
Sorarù, Mariella
Santoni, Matteo
Cortellini, Alessio
Prati, Veronica
Soto Parra, Hector Josè
Santini, Daniele
Atzori, Francesco
Di Napoli, Marilena
Caffo, Orazio
Messina, Marco
Morelli, Franco
Prati, Giuseppe
Nolè, Franco
Vignani, Francesca
Cavo, Alessia
Roviello, Giandomenico
Rescigno, Pasquale
Buti, Sebastiano
Article History
Received: 11 July 2022
Accepted: 18 August 2022
First Online: 30 September 2022
Declarations
:
: The study was approved by the regional ethical committee (Regional Ethical Committee of Liguria—registration number 068/2019). It was performed according to the Declaration of Helsinki, Good Clinical Practice and local ethical guidelines. All living patients enrolled in the study signed a written informed consent and all medical data used in this study were anonymized.
: Informed consent was obtained from all the patients enrolled in the study.
: Dr Rebuzzi received honoraria as speaker at scientific events BMS, Amgen, GSK. Dr Buti received honoraria as speaker at scientific events and advisory role by BMS, Pfizer, MSD, Ipsen, Roche, Eli Lilly, AstraZeneca, Pierre-Fabre, Novartis. Dr Fornarini services advisory boards for Astellas, Janssen, Pfizer, Bayer, MSD, Merck and received travel accomodation from Astellas, Janssen, Bayer. Dr Rescigno services advisory boards for MSD, AstraZeneca and Janssen. Dr Banna reports personal fees from AstraZeneca, Janssen-Cilag, Boehringer Ingelheim, Roche and non-financial support from BMS, AstraZeneca, MedImmune, Pierre Fabre, IPSEN. Dr De Giorgi services as advisory/board member of Astellas, Bayer, BMS, IPSEN, Janssen, Merck, Pfizer, Sanofi, received research grant/funding to the institution from AstraZeneca, Roche, Sanofi and travel/accommodations/expenses from BMS BMS, IPSEN, Janssen, Pfizer. Dr Zucali reports outside the submitted work personal fees for advisory role, speaker engagements and travel and accommodation expenses from Merck Sharp & Dohme (MSD), Astellas, Janssen, Sanofi, Ipsen, Pfizer, Novartis, Bristol Meyer Squibb, Amgen, AstraZeneca, Roche, and Bayer. Dr Procopio services advisory boards/consulting for Astellas, AstraZeneca, BMS, Janssen, IPSEN, Merk, MSD, Novartis, Pfizer. Dr Sorarù services advisory boards/consulting for Janssen, received research funding from Janssen and received travel accomodation from Ipsen, BMS, Janssen, Pfizer, Astellas Pharma. Dr Cortellini received speaker fees and grant consultancies by Astra Zeneca, MSD, OncoC4 and EISAI. Dr Morelli received grants from MSD, Pfizer. The other authors have no conflicts of interest to disclose.